AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12457671
Drug: Fentanyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (5 microg bolus doses via PCA after IV loading dose of 0.7 microg/kg)
Trial: 12457671
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (balanced salt solution without analgesic via PCA)
Trial: 10542999
Drug: C1-inhibitor administration
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor administration
Trial: 8949757
Drug: twice‐daily neutron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice‐daily neutron therapy for advanced head and neck cancer
Trial: 8949757
Drug: neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutron therapy for advanced salivary gland tumours
Trial: 8949757
Drug: neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutron therapy for locally advanced breast cancer
Trial: 8949757
Drug: neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutron therapy for macroscopic residual soft tissue sarcomas
Trial: 8949757
Drug: neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutron therapy for macroscopic residual uterine sarcoma
Trial: 8949757
Drug: neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutron therapy for advanced squamous carcinoma of the maxillary antrum
Trial: 8949757
Drug: neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutron therapy for advanced osteosarcomas and chondrosarcomas
Trial: 1681558
Drug: Loprazolam 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loprazolam 2 mg
Trial: 28261955
Drug: Beloranib 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beloranib 1.8 mg subcutaneously twice weekly for 4 weeks
Trial: 28261955
Drug: Beloranib 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beloranib 1.8 mg (after 4-week open-label extension)
Trial: 28261955
Drug: Beloranib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beloranib treatment
Trial: 20932798
Drug: 6.4% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% maltodextrin solution [Mal]
Trial: 20932798
Drug: 7.1% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.1% glucose solution [Glu]
Trial: 31441852
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (continuous infusion with 0.01 mg/kg/h and a bolus dose with 0.03 mg/kg)
Trial: 31441852
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (a bolus dose with 0.03 mg/kg)
Trial: 31441852
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (PCA administered as a time‐scheduled decremental continuous infusion based on lean body mass)
Trial: 21912321
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (control)
Trial: 16962938
Drug: High phenolic
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High phenolic content virgin olive oil (25 ml/day for 3 weeks)
Trial: 11193166
Drug: Talsaclidine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talsaclidine (selective muscarinic M1 agonist), administered for 4 weeks
Trial: 11193166
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group), administered for 4 weeks
Trial: 9076645
Drug: Estrogen implant
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen implant
Trial: 3790956
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g IV/8 h for 2 days)
Trial: 3790956
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g IV on induction and 12 h postoperatively)
Trial: 23011911
Drug: Chemoradiation (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation (CRT) with concurrent 5-fluorouracil/mitomycin C
Trial: 15521216
Drug: Ozonated autohemotherapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonated autohemotherapy (O3‐AHT) with ozone concentration of 50 microg/ml
Trial: 9726386
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lansoprazole/day
Trial: 9726386
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine/day
Trial: 9726386
Drug: Termination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Termination of therapy
Trial: 8027291
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml insemination
Trial: 8027291
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml insemination
Trial: 2572101
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with MC 903 (new synthetic vitamin D3 analogue)
Trial: 28522917
Drug: Xiangbin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiangbin prescription (XBP)
Trial: 23893178
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (partial substitution)
Trial: 9183321
Drug: Wheat starch-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat starch-containing product (4 to 6 portions daily for up to 1 year)
Trial: 31130959
Drug: Glucocorticosteroids and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroids and/or adjuvant immunosuppressive drugs
Trial: 31130959
Drug: Novel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel treatment targets
Trial: 23867622
Drug: Daily 2-hour
RxNorm normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 2-hour cold exposure at 17°C for 6 weeks
Trial: 23867622
Drug: Daily ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of capsinoids for 6 weeks
Trial: 16361874
Drug: Brief Strategic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Strategic Family Therapy (BSFT) for 3 months
Trial: 8968170
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg orally 2 h before induction and an infusion of 0.1 mg.kg‐1.h‐1 for 23 h)
Trial: 1477874
Drug: artemether (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artemether (n = 24), 9.6 mg/kg body weight intramuscularly over five days
Trial: 1477874
Drug: chloroquine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chloroquine (n = 23), 25 mg/kg body weight orally
Trial: 3511402
Drug: Progabide (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progabide (32 mg/kg mean daily dose, range 16 to 63)
Trial: 22082089
Drug: PROMETA Protocol
RxNorm normalized name: Promacta
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PROMETA Protocol (flumazenil 2 mg infusions on days 1, 2, 3, 22, 23; gabapentin 1200 mg to day 40; hydroxazine 50 mg to day 10)
Trial: 22082089
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication (with active hydroxazine only)
Trial: 12664022
Drug: Mizolastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (10 mg, once daily)
Trial: 10630824
Drug: Cefepime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime administered as an intravenous bolus or as a rapid infusion
Trial: 2355106
Drug: HP 029
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 029 at 450 mg/day (150 mg three times a day)
Trial: 2355106
Drug: HP 029
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 029 at 300 mg/day (100 mg three times a day)
Trial: 2355106
Drug: HP 029
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 029 at 225 mg/day (75 mg three times a day)
Trial: 322539
Drug: Pethidine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine at two dose levels
Trial: 23764202
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist withdrawal
Trial: 23764202
Drug: Control (non-withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-withdrawal of GnRH agonist)
Trial: 17146416
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 75-300 mg/day
Trial: 14633326
Drug: Trastuzumab added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab added to standard chemotherapy in HER2 positive metastatic breast cancer
Trial: 11052243
Drug: Intravenous thiopental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thiopental followed by mask inhalation with 100% O2 and 1.13% halothane
Trial: 11052243
Drug: Intravenous thiopental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thiopental followed by mask inhalation with 2.52% enflurane
Trial: 11052243
Drug: Intravenous thiopental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thiopental followed by mask inhalation with 1.73% isoflurane
Trial: 11052243
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam and ketamine
Trial: 11052243
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam and alfentanil
Trial: 3769402
Drug: Capsaicin injection
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin injection (0.5 micrograms/kg and 4 micrograms/kg)
Trial: 3769402
Drug: Capsaicin injection
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin injection after inhalation of 5% bupivacaine aerosol
Trial: 3769402
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (not specified)
Trial: 21036883
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy plus chemoradiotherapy
Trial: 18416793
Drug: Acupressure and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure and meridian massage (15 minutes per session, 3 times daily for 10 days)
Trial: 6452793
Drug: Zimelidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (100 mg b.i.d.)
Trial: 2939691
Drug: Maprotiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (75 mg b.i.d.)
Trial: 20669296
Drug: Melevodopa/carbidopa effervescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melevodopa/carbidopa effervescent tablets (M/C)
Trial: 20669296
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral formulation levodopa/carbidopa tablets (L/C)
Trial: 16013016
Drug: Biocompatible treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible treatments (on-line hemofiltration or HD with ultra-pure dialysate and biocompatible membranes)
Trial: 16013016
Drug: Biocompatible treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible treatments
Trial: 9624239
Drug: low‐dose short‐term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐dose short‐term chemotherapy (one cycle of doxorubicin, vincristin (AV) and one cycle of cyclophosphamide, methotrexate, fluorouracil (CMF))
Trial: 8091320
Drug: Ventstream nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventstream nebuliser at 5.0 mg dose
Trial: 27546446
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (36 IU)
Trial: 22406757
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg of alcohol
Trial: 18759645
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) 10, 15, 20, or 30 mg/9 h
Trial: 3596050
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of BCG in enteric-coated capsules
Trial: 3596050
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without BCG administration
Trial: 2493409
Drug: Energy‐Nitrogen Dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy‐Nitrogen Dense diet (1.5 kcal/ml; 9.4 gN/l)
Trial: 2493409
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet (1.0 kcal/ml; 6.3 gN/l)
Trial: 2493409
Drug: Energy Dense
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy Dense diet (1.5 kcal/ml; 7.8 gN/l)
Trial: 27995228
Drug: 15% Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% Chitosan gel
Trial: 21741057
Drug: Metreleptin (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (initial dose, 0.08 mg/[kg·d] for 3 months; altered to 0.12 mg/kg or 0.04 mg/[kg·d])
Trial: 19567900
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) by a general practitioner
Trial: 19567900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Colour Your Life and TAU
Trial: 9164692
Drug: linopirdine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linopirdine (30 mg three times per day)
Trial: 3299395
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice daily for 2 weeks
Trial: 3299395
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice daily plus Verapamil 160 mg twice daily for 4 weeks
Trial: 3299395
Drug: Verapamil 160
RxNorm normalized name: verapamil 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 160 mg twice daily for 4 weeks
Trial: 28664750
Drug: Preemptive Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive Ethanol Lock Therapy (ELT)
Trial: 28664750
Drug: Rescue Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rescue Ethanol Lock Therapy (ELT)
Trial: 26917477
Drug: Gestrinone 2.5
RxNorm normalized name: gestrinone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 2.5 mg, twice a week for three months
Trial: 26917477
Drug: Gestrinone double
RxNorm normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone double dose first month, then twice a week for two months
Trial: 26917477
Drug: Gestrinone treatment
RxNorm normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone treatment
Trial: 25569481
Drug: Standard-care control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care control group (C-G)
Trial: 20498392
Drug: Genetic information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic information regarding cognitive impairment risk (CI) after chemotherapy
Trial: 16926710
Drug: High-dose alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alcohol preload
Trial: 8777169
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy followed by high-dose split course radiotherapy (CT + RT)
Trial: 8777169
Drug: High-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiotherapy only (RT only)
Trial: 1440306
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg/day
Trial: 1725550
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 120 mg/day diltiazem and 20 mg/day nitrendipine
Trial: 6409196
Drug: L-Deprenil treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Deprenil treatment
Trial: 22312088
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment of chronic cerebro-spinal venous insufficiency
Trial: 18692615
Drug: SILCS diaphragm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SILCS diaphragm with 2% nonoxynol-9 (N-9) gel
Trial: 18692615
Drug: SILCS polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SILCS polymer spring diaphragm with 2% nonoxynol-9 (N-9) gel
Trial: 16062021
Drug: 0.5% 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% 20 ml bupivacaine
Trial: 16062021
Drug: 0.5% 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% 20 ml bupivacaine with 1 microg/kg clonidine
Trial: 12373696
Drug: 8 mL
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL 0.9% NaCl (group I)
Trial: 12373696
Drug: 8 mL
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL (5 mg) atracurium (group II)
Trial: 10544340
Drug: Tetracycline eye
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline eye ointment administered by Village Treatment Assistants (VTAs) daily for four weeks.
Trial: 2093019
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 or 40 mg daily
Trial: 2093019
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg daily (maintenance)
Trial: 2093019
Drug: Omeprazole weekend
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole weekend therapy (20 mg daily on Fri, Sat, Sun)
Trial: 74302
Drug: Combination schedule
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination schedule containing adriamycin
Trial: 74302
Drug: Combination schedule
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination schedule without adriamycin
Trial: 10629345
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no antithrombotic therapy
Trial: 1994417
Drug: Oral superparamagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral superparamagnetic contrast agent (800 mL ingested over approximately 2 hours)
Trial: 30644302
Drug: arthroscopic debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arthroscopic debridement and a subsequent intra‐articular injection of autologous micro‐fragmented adipose tissue
Trial: 26691932
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied immediately after extraction
Trial: 21692147
Drug: Theoretical formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theoretical formulations regarding medial temporal contributions
Trial: 17599424
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy for diabetes-related dyslipidemia
Trial: 2012453
Drug: Full-dosage zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dosage zidovudine (1200 mg/d)
Trial: 2012453
Drug: Reduced dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced dosage zidovudine (600 mg/d)
Trial: 2012453
Drug: No dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dosage change
Trial: 7258744
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination drug product containing triprolidine and pseudoephedrine
Trial: 31430763
Drug: 670 nm red
RxNorm normalized name: Red gum
DrugBank: Eucalyptus gum (DB15537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 670 nm red light treatment (15 min daily until 34 weeks corrected age, 9 J/cm2)
Trial: 22316314
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation (average daily dose 10,200 IU)